Advancing Medical Science with Rebase BioTech

Through our partnership with the University of Minnesota, we operate a cutting-edge research facility complete with state-of-the-art technology and equipment. This includes a dedicated, modern research lab spanning 5,000 square feet, fully equipped for chemistry and biology research, including animal studies, enabling us to pioneer groundbreaking research and drive new discoveries.

Our team of researchers, led by the vastly experienced Dr. Venkatram Mereddy, is passionate about advancing medical science and improving patient outcomes through innovative research. Professor Mereddy is a co-author/inventor of 6 patents, ~100 peer reviewed publications and more than 50 meeting papers. His research area is in drug development of small molecule anticancer, antimicrobial, and disease modifying therapeutics for liver diseases.

Our research is characterized by its innovative approach, leveraging the latest advancements in AI, medicinal chemistry, pharmacology, genetic differences in cancer, and targeted therapy. We believe in harnessing the power of science to create meaningful and lasting change.

We are at the forefront of cancer research. Our multidisciplinary team of scientists and researchers are committed to pushing the boundaries of knowledge and developing groundbreaking solutions that provide selective delivery of cytotoxic agents to tumor site without the use of antibodies and achieving synthetic lethality in BRCA mutated cancers through new mechanisms for the benefit of patients with difficult to treat cancers.

Our commitment to scientific excellence is unwavering. Our research team comprises some of the brightest minds in medicinal chemistry, pharmacology, and oncology. We maintain rigorous quality standards in all our research endeavors. We are proud of our contributions to the scientific community and our dedication to advancing knowledge.

We believe in the power of collaboration. Rebase Biotech collaborates with leading scientists at University of Minnesota to accelerate the translation of our research into real-world solutions. We use world class research facilities available at the university to carry out the synthesis, characterization, in vitro and in vivo evaluation of novel drug candidates as new generation anticancer agents. Together, we aim to reshape the landscape of pancreatic and liver cancers through collaborative innovation.

Targeted delivery of candidate drugs without the use of antibodies. Our work in this area utilizes innovative drug delivery of highly potent cytotoxic agents selectively to tumor sites. These selective agents do not use any antibodies and do not have the need to release the payloads inside the tumor. Our commitment to innovation and excellence drives our efforts in this critical area.

Development of targeted therapies by exploiting the genetic differences in cancers. Our work in this area has identified several candidate drugs which achieve synthetic lethality in BRCA mutated cancers through new molecular mechanisms of action. These agents also overcome resistance to clinically used PARP inhibitors.